Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)-Reference-Cited by-同舟云学术

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

Published:2022-05 Issue:2 Volume:109 Page:2S19-2S30
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:en
Short-container-title:Bulletin du Cancer

Author:

Kaddissi Antoine El,Ducleon Guillemette Guilhem,Lefort Félix,Mezepo Garvey,Frontczak Alexandre,Goujon Morgan,Mouillet Guillaume,Almotlak Hamadi,Gross-Goupil Marine,Thiery-Vuillemin Antoine

Funder

Ipsen

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference30 articles.

1. Epidemiology and screening for renal cancer;Rossi;World J Urol,2018

2. Clinical activitiy of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient;Borchiellini;Bulletin du Cancer,2022

3. Check-Mate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma;Motzer;N Engl J Med,2018

4. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial;Cella;Lancet Oncol,2019

5. Check-Mate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial;Motzer;Lancet Oncol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic Renal-Cell Carcinoma of the Oro-Facial Tissues: A Comprehensive Review of the Literature with a Focus on Clinico–Pathological Findings;Surgeries;2024-08-18

2. Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient;Bulletin du Cancer;2022-05